Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Total Non-Current Liabilities (2021 - 2026)

Elicio Therapeutics filings provide 3 years of Total Non-Current Liabilities readings, the most recent being $15.8 million for Q4 2023.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $15.8 million in Q4 2023 year-over-year; TTM through Dec 2023 was $15.8 million, a N/A change, with the full-year FY2023 number at $15.8 million, changed N/A from a year prior.
  • Total Non-Current Liabilities hit $15.8 million in Q4 2023 for Elicio Therapeutics, up from $11.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $15.8 million in Q4 2023 to a low of $11.0 million in Q2 2022.
  • Median Total Non-Current Liabilities over the past 3 years was $14.4 million (2021), compared with a mean of $13.9 million.